Open Access Open Access  Restricted Access Subscription or Fee Access

A Review Drug and Biochemical Pharmacology Discovery

Nisha TK, Vinay V. Raman, Asavari Santosh Pate, Sohini Sen, Joginder Singh, R. Naga Kishore

Abstract


The development of new therapeutic approaches and our understanding of disease mechanisms have both benefited ground-breaking medications as they are advanced and show the value of contemporary technologies, methodologies, and genetics in drug discovery. The synthesis, design, and application of these molecules have become a focal point in drug discovery efforts. The present research paper provided a comprehensive study of the recent developments in the field of biochemical pharmacology and drug discovery. Through an analysis of current literature, the present paper highlighted the emerging trends, novel methodologies, and discoveries that significantly advanced our understanding of disease mechanisms and propelled the discovery of innovative drugs. The paper also discussed the challenges faced in the field and explored potential future directions for continued development in biochemical and drug discovery, greatly from recent work in biochemical pharmacology and drug discovery. The issues that the pharmaceutical industry is currently facing were also discussed in the present study. These challenges include declining rates of drug discovery and increasing costs associated with bringing a new drug to the market. Researchers are able to streamline the drug development process by targeting molecules or pathways that play a crucial role in disease progression by identifying specific biomarkers. This targeted approach has the potential to increase the success rate of clinical trials and decrease the overall costs of drug development. Additionally, the collaboration between academia, the pharmaceutical industry, and biochemical researchers has paved the way for novel drugs.

Keywords


Biochemical pharmacology, drug discovery, disease mechanism, novel drugs, future directions.

Full Text:

PDF

References


Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nature Chemical Biology. 2008; 4(11): 682–690p.

Gaulton A, Hersey A, Nowotka M, Bento AP, Chambers J, Mendez D, Mutowo P, Atkinson F, Bellis LJ, Cibrián-Uhalte E, Davies M. The ChEMBL database in 2017. Nucleic Acids Research. 2017; 45(D1): D945–D954.

Drews J. Drug discovery: A historical perspective. Science. 2000; 287(5460): 1960–1964p.

Goh KI, Cusick ME, Valle D, Barabasi AL. The human disease network. Proc Natl Acad Sci USA. 2007; 104(21): 8685–8690p.

Eric ES. Molecular networks as sensors and drivers of common human diseases. Nature. 2009; 461(7261): 218–223p.

Nelson MR, Tipney H, Painter JL, Shen J, Nicoletti P, Shen Y, Floratos A, Sham PC, Li MJ, Wang J, Cardon LR, Whitaker JC. The support of human genetic evidence for approved drug indications. Nat Genet. 2015; 47(8): 856–860p.

Yanghe F, Qi W, Tengjiao W. Drug target discovery through network analysis: computational considerations. Curr Pharm Des. 2010; 16(17): 1897–1908p.

Silwoski G, Kothiwale S, Meiler J, Lowe EW. Computational methods of drug discovery. Pharmacol Rev. 2014; 66(1): 334–395p. 9. Johnson B, Loree JM, Jacome AA. Atypical, Non-V600 BRAF mutations as a potential mechanism of resistance to EGFR inhibition in metastatic colorectal cancer. JCO Precis Oncol. 2019; 3: PO.19.00102. doi: 10.1200/PO.19.00102.

Smith MP, Ferguson HR, Ferguson J, Zindy E, Kowalczyk KM, Kedward T, Bates C, Parsons J, Watson J, Chandler S. Reciprocal priming between receptor tyrosine kinase at recycling endosomes orchestrates cellular signaling outputs. The EMBO J. 2021; 40: e107182. doi: https://doi.org/10.15252/embj.2020107182.

Melone V, Salvati A, Palumbo D, Giurato G, Nassa G, Rizzo F, Palo L, Giordano A, Incoronato M, Vitale M, Mian C, Di I, Cristiano S. Identification of functional pathways and molecular signatures in neuroendocrine neoplasms by multi-omic analysis. J Trans Med. 2022; 20: 306p.

Boobphahom S, Ly NM, Soum V, Pyun N, Kwon OS, Rodthongkum N, Shin K. Recent advances in microfluidic paper-based analytical devices toward high throughput screening. Molecules. 2020; 25(13): 2970p. doi: 10.3390/molecules25132970.

Gawriljuk VO, Zin PPK, Puhl AC, Zorn KM, Foil DH, Lane TR, Hurst B, Tavella TA, Costa FTM, Lakshmanane PK, Godoy AS. Machine learning models identify inhibitors of SARS-CoV-2. J Chem Inf Model. 2021; 61(9): 4224–4235p.

Nitesh MT, Anupam B. High throughput virtual screening (HTVS) of peptide library: technological advancement in ligand discovery. Eur J Med Chem. 2022; 243:114766. doi: 10.1016/j.ejmech.2022.114766.

Malapaka VRR, Barrase AA, Tripp BC. High throughput screening for antimicrobial compounds using a 96-well format bacterial motility absorbance assay. J Biomol Screen. 2007; 12(6): 849–854p. doi: 10.1177/1087057107304478.

Xin PH. Pterocarpans and their biological activities: A review. Chin Med J. 2021; 46(17): 4323–4333p.

Siveen KS, Sikka S, Surana R, Dai X, Zhang J, Kumar AP, Tan BKH, Sethi G, Bishayee A. Targeting the STAT3 signaling pathway in cancer: role of synthetic and natural inhibitors. Biochim Biophys Acta. 2014; 1845(2): 136–154p. doi: 10.1016/j.bbcan.2013.12.005.

Roy A, Khan A, Ahmad I, Alghamdi S, Rajab BS, Babalgith AO, Alshahrani MY. Flavonoids a Bioactive Compound from Medicinal Plants and Its Therapeutic Applications. Biomed Res Int. 2022; 2022: 5445291. doi: 10.1155/2022/5445291.

Nuzzo G, Senese G, Gallo C, Albiani F, Romano L, Manzo E, Fontana A. Antitumor Potential of Immunomodulatory Natural Products. Mar Drugs. 2022; 20(6): 386p. doi: 10.3390/md20060386. 20. Liu Y, Zhang Q, Qi X, Gao H, Yu B. Metabolic engineering of Bacillus subtilis for riboflavin production: A review. Microorga. 2023; 11(1): 164pzfedcwaSS. doi: http://doi.org/10.3390/microorganisms11010164




DOI: https://doi.org/10.37591/rrjomst.v12i3.3305

Refbacks

  • There are currently no refbacks.


Copyright (c) 2023 Research & Reviews: Journal of Medical Science and Technology